G-protein-coupled receptor kinases (GRKs) mediate agonist-specific phosphorylation and desensitization of G-protein-coupled receptors. Previous studies have shown that several of these kinases are expressed in hematopoietic cells and that GRK expression is modulated during T-lymphocyte activation. Here, w e analyzed the regulation of B-adrenergic receptor kinase (BARK) and GRKG expression and activity in myelomonocytic and lymphoid cells. In the promyelocytic cell line HL-60, GRKG protein levels and activity rose twofold to fourfold over the course of treatment with agents that induce differentiation toward either the myeloid (dimethyl sulfoxide and retinoic acid) or monocytic [la,25(OHI2-vitamin Do] lineage, whereas BARK protein levels and activity -PROTEIN-COUPLED receptors mediate numerous intracellular signaling pathways on binding extracellular agonists (ie, hormones, neurotransmitters, odorants, and Receptors of this type regulate a variety of effector molecules such as adenylyl cyclase, cGMP phosphodiesterase, phospholipases A2 and C, and numerous ion channels. Two of the best studied G-protein-coupled receptors are the ,&-adrenergic receptor (P2AR)2, which mediates catecholamine stimulation of adenylyl cyclase, and the visual light receptor rhodopsin, which facilitates phototransduction in retinal rod cells.334 In both systems a rapid diminution of responsiveness or desensitization occurs following receptor Activation-dependent desensitization is mediated in part by specific G-protein-coupled receptor kinases (GRKs) that have the unique ability to recognize and phosphorylate their receptor substrates only when they are in an active c~nforrnation.~*' The @-adrenergic receptor kinase (PARK) and rhodopsin kinase have been implicated as the major kinases involved in the stimulus-dependent phosphorylation of the P2AR and rhodopsin, Subsequent uncoupling of the receptor from the G protein is promoted by arrestin proteins that specifically bind to the phosphorylated and activated form of the re~eptor.'.~ PARK and rhodopsin kinase are members of a multigene family of related kinases. Structural information on the GRK family was initially provided by the isolation of a cDNA encoding bovine PARK.I2 PARK is a 689-amino acid protein (79.6 kD) containing a protein kinase catalytic domain flanked by large amino-and carboxyl-terminal domains. Additional members of the GRK family were subsequently ~l o n e d . " "~ GRK6, the most recently identified member, is a 576-amino acid protein (66 kD) that has relatively low (35%) amino acid identity with PARK.'' In vitro studies demonstrate that GRK6 phosphorylates receptor substrates such as the P,AR, m2AChR, and rhodopsin with significantly less activity than PARK, suggesting that GRK6 and PARK have distinct substrate specificities in vivo. '' Tissue distribution of GRK6 is most similar to PARK with mRNA expression highest in brain and skeletal muscle." PARK, PARK2, GRK5, and GRK6 are also expressed in peripheral blood lymphocytes (PBL), neutrophils, and a number of myeloid and lymphoid cell lines.20-22 Within the family of G-protein-coupled receptors is a group of proteins (termed chemokine receptors), expressed on human myelomonocytic and lymphoid cells, that mediate events during inflammatory and immune responses like cell chemotaxis and activation. These receptors are activated by specific peptide chemoattractants such as N-formylated peptides (fMLP), interleukin-8 (IL-8), C5a, and the lipid-derived chemoattractants platelet-activating factor (PAF) and leukotriene B4.23 While at present no direct association between chemokine receptor desensitization and GRK-mediated phosphorylation has been demonstrated, it is likely that desensitization of these and other G protein-linked receptors is mediated, at least in part, by GRKs. This possibility is supported by several lines of evidence: (1) Several chemokine receptors expressed on granulocytes (ie, C5a, fMLP, MCP-1, and MCPla receptors) undergo agonist-specific desensiti~ation'~-~~; (2) IL-8 receptors transfected into human kidney and placenta cell lines undergo agonist-induced receptor phosphoryl a t i~n~~; (3) PAF has been shown to induce translocation of PARK from cytosol to membrane in PBLZ0; and (4) Agonistdependent phosphorylation of the PAF, fMLP, and C5a receptors has been demonstrated in vivo and these proteins appear to be good substrates for PARK in ~itro.~'.'~ Recent studies have demonstrated enhanced PARK expression and activity in phytohemagglutinin (PHA)-activated PBL.22 These data may suggest an important functional link between regulated expression of GRKs and the activatiorddifferentia-
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MATERIALS AND METHODS
Materials. Dimethylsulfoxide (DMSO), phorbol myristic acetate (PMA), all-trans retinoic acid (RA), lipopolysaccharide (LPS), phytohemagglutinin (PHA), and the calcium ionophore A23187 were purchased from Sigma Chemical CO (St Louis, MO) and la,25(0H),-Vitamin D, and l-oleoyl-2-acetyl-sn-glycerol (OAG) were from Calbiochem Corp (La Jolla, CA). [a"P]dCTP was purchased from DuPont-NEN (Boston, MA).
Cells. All cell lines and human PBL were maintained at 37°C in RPM1 1640 culture medium (GIBCO BRL Products, Grand Island. NY) supplemented with 10% fetal bovine serum (Sigma), 2 mmol/ L glutamine, 50 U/mL penicillin, and 50 pg/mL streptomycin. Monocytes were cultured at 37°C in the same medium supplemented with 5% human serum, 2 mmol/L glutamine, and antibiotics. Adult peripheral blood mononuclear cells (PBMC) were isolated from healthy individuals by differential centrifugation on Ficoll-Hypaque density gradient (Lymphoprep, Nyegaard and CO, Oslo, Norway). Monocytes were purified after adherence of PBMC to plastic petri dishes for 1 hour at 37"C, followed by gentle washing with phosphate-buffered saline (PBS) three times to remove nonadherent cells. Monocytes were cultured for 3 days on plastic dishes with or without 5 pg/mL LPS. PHA blasts were generated from PBL (lo6 cells/mL) cultured with 1 pg/mL PHA for 1, 3, and 5 days. When indicated, PBL (10' cellslml) were stimulated with PMA (lo-' mol/L) and A23187 (0.1 pg/mL) for 2, 4, 8, 24, 48, and 72 hours. The anti-CD3 monoclonal antibody OKT-3 was adsorbed to nontissue culture petri dishes, 18 hours at 4"C, in sterile 0.1 mol/L sodium bicarbonate buffer, pH 9.5. The plates were washed three times with PBS and 3 X IO6 PBL/mL were added in the presence of 50 U/mL recombinant human IL-2 for 3, 5, and 7 days. HL-60 cells were cultured (0.2 X 10' cells/mL) with 1.2% DMSO, IO-' mol/L PMA, IO" mol/L RA, or 10" m o l L 10,25(OH),-Vitarnin D, for 3 and 5 days or with 20 pg/mL OAG for 1, 2, and 3 days. Morphological changes after culture with the various inducers were analyzed by GeimsaWright's staining and light microscopy.
Northern blot analysis. Total RNA was isolated from the different cell types using the RNAzol method (Tel-Test, Inc, Friendswood, TX) and electrophoresed (10 pgnane) on 0.8% agarose-formaldehyde gels, transferred to 0.2 mm nitrocellulose membranes using a Turboblotter apparatus (Schleicher and Schuell, Keene, NH), and immobilized with a Stratalinker UV light source. In each experiment equivalent loading of RNA was assessed by ethidium bromide staining (data not shown). A 1780-bp EcoRI open-reading frame fragment of the human GRK6 clone pGRK6-hh2" was labeled with [a3*P]-dCTP by random-priming and used for hybridization at 2 to 3 X 10' cpm/mL in the presence of hybridization buffer (25% formamide, 5 x SSC, 5x Denhardt's solution, 1% sodium dodecyl sulfate (SDS), 0.1 % tetrasodium pyrophosphate and 0.1 mg/mL sonicated salmon sperm DNA), 20 hours at 42°C. The membranes were washed three times in 2 x SSC/O.3% SDS at room temperature for 30 minutes and three times in 0 . 2~ SSC/O.3% SDS at 60°C for 30 minutes, then exposed to Fuji-RX film (Fuji Film CO, Tokyo, Japan) at -70°C for 7 to 48 hours. PARK mRNA expression was determined on the same filters, after being stripped with boiling 0.1% SDS, using a 718-bp Sac1 open-reading frame fragment corresponding to the catalytic domain of bovine PARK." Hybridization and washings were performed as described above.
Western blot unalysis. Cells (2 to 5 X IO" from the various cell types) were lysed in 100 FL of 20 mmoVL HEPES, pH 7.5, 1 % Triton-X 100, 150 mmol/L NaCI, 10 mmol/L EDTA, 0.5 mmollL phenylmethylsulfonyl fluoride, 20 pg/mL leupeptin, and 200 pg/mL benzamidine. Lysates were centrifuged at 1 5 , 0 0 0~ for 5 minutes at 4°C and supernatants recovered. Between 20 and 40 pg of protein from each lysate (measured with Bio-Rad [Hercules, CA] protein assay kit) was electrophoresed on a 7.5% SDS-polyacrylamide gel,3' transferred to nitrocellulose membranes, washed in Tris-buffered saline, pH 7.5, and blocked for 1 hour in 0.05% Tween-Tris-buffered saline (TTBS) with 5% (wt/vol) dried, nonfat milk. An affinitypurified rabbit polyclonal antibody raised against a glutathione Stransferase (GST) fusion protein containing the 39-amino acid sequence of human GRK6 from Arg98 to Gly136 [GST-GRK6(98-136)] was used for Western blotting. The antibody was aftinitypurified on a GST-GRK6(98-136)-Affigel I O agarose column (BioRad: 1 mg fusion proteidmL resin). Antibodies reactive to the GST were subsequently removed by adsorption to GST-Affigel 10 agarose ( I 9 mg GST/mL resin). The affinity-purified antibody does not crossreact with PARK, PARK2, GRK4, or GRK5. After incubation with primary antibodies, the filters were washed six times, I O minutes each, with TTBS and incubated for 1 hour at room temperature with affinity-purified goat antirabbit IgG conjugated to horseradish peroxidase (Bio-Rad) in 5% milk-PBS. Filters were washed five times in TTBS and visualized by Enhanced Chemi-luminescence (ECL; Amersham, Buckinghamshire, UK). For all experiments, duplicate membranes were prepared in which the anti-GRK6 antibodies used for immunoblotting were preincubated for 1 hour with 20 pg/ mL of GST-GRK6 (98-136) to assess GRK6-specific binding. In all cases, binding of the affinity-purified antibody to purified human recombinant GRK6'" and to the 67-kD immunoreactive band detected in cell lysates was completely inhibited under these conditions (data not shown). PARK protein expression was determined using a mouse monoclonal antibody, 3A10, raised against purified recornbinant bovine PARK. Antibody 3A10 recognizes a domain in the C-terminal region of bovine PARK that is identical in sequence to human PARK (R. Sterne-Marr, R. Bodine, and J. L. Benovic, unpublished results, March 1995). This antibody does not crossreact with PARK2, GRK4, GRK5, or GRK6 (data not shown). Immunoblotting was performed as described above, except that affinitypurified goat antimouse IgG conjugated to horseradish peroxidase (Bio-Rad) was used as the second antibody. Kinase levels in HL-60 cells, monocytes, neutrophils, and PBL were quantitated with a Personal Densitometer SI (Molecular Dynamics, Sunnyvale, CA) by comparing several different known amounts of purified recombinant PARK or GRK6 (from 0.5 to 4 ng of each kinase) with sample titrations (20 to 60 pg of lysates) on the same immunoblot. Several different exposure times of the x-ray film were done to ensure that the levels determined in the samples and standard kinase titrations were in the linear range of detection.
Immunoprecipitation and characterization of GRK6 activiry. A total of 5 to 10 X 10' HL-60 cells or PBL/5 day PHA blasts were lysed in 100 p L 1% Triton X-100 lysis buffer as described in Western blot analysis. Rabbit polyclonal antiserum raised against a GST fusion protein containing the C-terminal 102 amino acids of GRK5 (immunoreactive to both GRK5 and GRK6) was coupled to Protein . 20 mmol/L HEPES, pH 7.5. and 2 mmol/L EDTA), and incubated for 10 minutes in a 30°C shaking water bath. Kinase reactions were terminated with 20 pL SDS sample buffer. The samples were centrifuged briefly and then electrophoresed on a 10% SDS polyacrylamide gel. Gels were dried and autoradiography performed. Quantitation was performed by excising the phosvitin bands and counting in a Wallac 1209 Rackbeta scintillation counter. GRK6 activity was initially determined using equal numbers of cells per group, but it was subsequently determined that induction of HL-60 cells with DMSO, RA, and lc~,2S(OH),-vitamin D, decreased the per cell protein concentration 20% to 30%. For consistency with the GRK6 Western blot data, which was performed using identical amounts of protein for each sample, we adjusted the GRK6 activity values to represent the percent of kinase activity relative to control lysates for equivalent amounts of protein.
Partialpur$cation and characterization of BARK activity. Cells (50 to 170 x IO6 HL-60 cells and S0 to 100 x IO6 PBLPHA blasts) were lysed in 160 to 300 pL 1 % Triton X-I 0 0 lysis buffer as described above. Batch-wise SP-Sepharose chromatography was performed using 300 pL residtreatment group. After 1 hour incubation of the resin with cell lysates at 4°C on a rotator, the resin was washed four times with I mL wash buffer (2.0 mmol/L HEPES, pH We determined that the amount of PARK recovered in the IS0 mmol/L NaCl fraction from each lysate was -80% (data not shown) for all treatment groups. The amount and activity of PARK recovered from each group was reflected in Western blotting and rhodopsin phosphorylation assays of cell lysates before SP-sepharose chromatography, suggesting that the percent recovery of PARK was consistent among the induction groups.
RESULTS
Expression of GRK6 and PARK in hematopoietic cells. GRK6 and PARK mRNA and protein expression were analyzed in several lymphoid and myeloid cell lines and in peripheral blood lymphocytes, monocytes, and neutrophils from healthy individuals. A cDNA probe corresponding to the full-length GRK6 open reading frame detected two transcripts of -3.6 and 3 kb in most cell lines tested (Fig IA) , consistent with previous observations.'x The ratio of expression of the two mRNAs differed somewhat depending on the cells analyzed. The Jurkat T-cell line and two myeloid cell lines, U937 and HL-60, expressed both GRK6 mRNAs at levels more abundant than observed in RPMI-8866 (a Blymphoblastoid cell line), neutrophils. monocytes, and PBL (Fig IA) .
GRK6 protein content was analyzed by immunoblotting using an affinity-purified rabbit polyclonal antibody specific for GRK6. The antibody detected bands of -65 and -67 kD that were most abundant in the T-cell and myeloid cell lines (Fig IB, lanes 2 to 4) , while RPMI-8866 (lane I ) contained the lowest amount of GRK6. Overall, the differences in protein expression among the cell lines correlate reasonably well with differences observed in GRK6 mRNA levels. Two GRK6 immunoreactive bands of -65 and -67 kD were also detected in immunoblots of human neutrophil and PBL lysates (Fig IB, lanes 6 and 8) . In contrast, monocytes (lane 7) contained the 65-kD immunoreactive protein predominantly, while the -69 and -90 kD bands observed in monocyte lysates appear to be nonspecific because they are not blocked by preincubation of the antibody with GST-GRK6(98-136) (data not shown). The presence of the 651 67-kD protein doublet appears to be due to proteolysis, as HL-60 and PHA blast cell lysates quick-frozen in liquid nitrogen display a single 67-kD immunoreactive band (see Figs 3A and SA, respectively). In addition, there is a greater reduction in GRK6 protein in primary cells (Fig 1, lanes 6  through 8) versus the cells lines (lanes I through 4) compared with the more moderate decrease observed in GRK6 transcript levels between the two groups. The reasons for this are not clear, however these findings might indicate either more extensive proteolysis of GRK6 in the primary cell samples andor posttranscriptional regulation.
PARK expression was also assessed in these cells. PARK mRNA levels (3.8-kb transcript) were highest in the myeloid and T-cell lines, while lower levels were detected in RPMI-8866 cells, neutrophils, monocytes, and PBL (Fig 2A) . Levels of PARK protein were roughly similar in the myeloid and T-cell lines, while RPMI-8866 cells expressed the lowest amounts of this protein (Fig 2B, lanes I through 4) . Among peripheral blood leukocytes, monocytes and PBL expressed significantly greater levels of PARK than neutrophils. Because PARK steady-state mRNA levels are similar in neutrophils, PBL, and monocytes, we cannot rule out the possibility of proteolysis and/or posttranscriptional regulation of PARK in neutrophils. Quantitative analysis of PARK and GRK6 levels was performed by Western blotting and comparison of kinase levels in the various cell types with known amounts of purified recombinant PARK and GRK6 ( Table 1) . The overall levels of PARK were -sixfold and threefold higher than those of GRK6 in PBL and monocytes, respectively, from the same individual donors (Table l) . Neutrophils expressed roughly fivefold and sevenfold less PARK (-8,200 molecules/cell) compared with monocytes (-39,000 molecules/cell) and PBL (-57,000 molecules/cell), respectively, whereas GRK6 levels were similar (9,000 to 13,000 molecules/cell) for all three primary cell cultures. The pattern of expression described here for GRK6 and PARK was reproducibly observed in PBL, monocytes, and neutrophils from several donors (Figs 1B and 2B and data not shown), although the levels of PARK and GRK6 protein expression were variable among donors ( Table I) . By comparison, HL-60 cells expressed -sixfold more PARK (-170.000 molecules/cell) than GRK6 (-27,000 molecules/cell) protein, while PARK and GRK6 expression in HL-60 cells was roughly threefold greater than the levels observed for both kinases in primary cells.
Expression of GRK6 and PARK in HL-60 cells. The promyelocytic cell line HL-60 has been used extensively as an in vitro model system to study myelomonocytic cell differentiation. DMSO (1.2%) and RA (10-7mol/L) induce these cells to differentiate towards the myeloid whereas PMA (lo-' m o m ) and Ia,25(0H)2-vitamin D3 ( mol/L) enable them to acquire characteristics of mature monocytes/ma~rophages.~~.~~ Morphological changes consistent with cells of myeloid or monocytic differentiation were detected on induction with the various compounds (data not shown). Northern blot analysis of induced HL-60 cells showed that DMSO, RA, and la,25(0H)2-vitamin D, stimulation resulted in a moderate reduction of both GRK6 transcripts by day 5, while PMA-treatment substantially decreased transcript levels by day 3 (Fig 3A) . In contrast, stimulation of HL-60 cells with RA enhanced GRK6 protein expression approximately twofold by day 5, while DMSOand 1a,25(OH)2-vitamin D3-treated cells exhibited GRK6 protein levels threefold to fourfold higher than control cultures ( Fig 3A and Table l) . PMA-treated HL-60 cells exhibited a modest -50% decrease in GRK6 protein expression over time relative to the more significant decrement observed in GRK6 mRNA levels ( Fig 3A and Table 1 ). PARK mRNA expression decreased slightly by day 5 on DMSO, RA, and la,25(OH)2-vitamin D, treatment, while PMA resulted in a more prominant decrease in PARK steady-state levels on day 3 relative to the other inducers (Fig 3B) . PARK protein expression in DMSO-, RA-, and la,25(0H)2.vitamin D3-treated cells correlated well with the changes observed in mRNA steady-state levels and did not vary significantly compared with control cells (Fig 3B and Table 1) . PMA treatment decreased PARK protein levels -50% by day 3 (Fig 3B and Table l) .
The reasons for the disparate expression patterns observed for GRK6 mRNA and protein in differentiated HL-60 cells are not readily apparent. However, in control versus DMSO-, RA-, and 1a,25(OH)2-vitamin D,-treated HL-60 cells, enhanced GRK6 and unaltered PARK protein accumulation does not appear to be due to changes in half-life of these proteins as determined by pulse-chase experiments (tln = -16 and -24 hours for GRK6 and PARK, respectively). * Inducedhesting ratios were calculated using identical amounts of protein for each sample.
t HL-60 values are from 5-day cultures, except OAG (3-day cultures).
* Numbers in parentheses indicates number of donors analyzed.
Instead, these results may reflect altered mRNA turnover or stability as a consequence of the various treatments. Indeed, a lack of positive correlation of mRNA and protein expression has been described for a variety of gene products in both cell lines and in primary cell culture^.^^-^*
The observation that PMA downregulates PARK and GRK6, whereas 1~~,25(OH)~-vitamin D3 did not alter PARK levels while enhancing GRK6 expression, suggested the possibility that the effects induced by PMA were independent of HL-60 cell differentiation. HL-60 cells cultured with OAG, a cell-permeable diacylglycerol analog that activates protein kinase C without inducing HL-60 cell differentiati~n:~.~ expressed substantially decreased levels of GRK6 by day 3, while PARK expression was not significantly altered (Table  1) . These results suggest that activation of PKC alone is sufficient to decrease steady-state protein levels of GRK6, while PARK levels are not significantly altered under these conditions. Furthermore, phorbol ester-induced factors other than the activation of PKC may account for decreased PARK expression in PMA-treated HL-60 cells.
PARK and GRK6 activity in differentiated HL-60 cells. To assess the functional significance of regulated GRK expression in hematopoietic cells PARK and GRK6 kinase activity was determined in differentiated HL-60 cells. Two strategies were devised to separate PARK and GRK6 to enable us to determine changes in kinase activity. One approach involved immunoprecipitation of GRK6 with a GRKS/GRK6 polyclonal rabbit antisera coupled to protein A agarose and assaying immune complexes for kinase activity against an exogenous substrate, phosvitin. It was necessary to use this nonreceptor substrate to assess GRK6 activity, as immunoprecipitation of GRK6 appears to block its ability to phosphorylate rhodopsin, but not phosvitin (data not shown). Immunoprecipitation of GRK6 and assessment of kinase activity showed an -2.5-fold enhancement of GRK6 activity versus uninduced HL-60 cells in 5-day DMSO-, RA-, and 1~~,25(0H)~-vitamin D,-treated cells (Fig 4A) . In contrast, 5-day PMA-treated cells exhibited GRK6 expression levels roughly 40% of control values, while kinase activity was -80% versus control cells (Fig 4A) . The reasons for this inconsistency are not known; however, these data might suggest a PMA-dependent increase in GRK6 activity, even though its expression is reduced. In all cases, GRK6 activity was significantly inhibited (>90%) when immunoprecipitations with the GRKYGRK6 antibody were done in the presence of a GST fusion protein containing the C-terminal 101 amino acids of GRKS (data not shown). Additionally, immunoprecipitation with preimmune serum did not result in any detectable kinase activity (data not shown). We cannot completely rule out the possibility that GRKS accounts for some of the observed activity in these assays. However, because HL-60 cells do not appear to express detectable levels of GRK5 mRNA or protein (data not shown), these results strongly suggest that modulation of GRK6 activity occurs in differentiated HL-60 cells. Unfortunately, the immunoprecipitation assay used for GRK6 could not be used for PARK because immunoprecipitation of PARK blocks rhodopsin phosphorylation, and there are no good nonreceptor substrates for this kinase (data not shown).
We next attempted to assess the activity of PARK in differentiated HL-60 cells. Thus, a second strategy to resolve specific GRK activities was devised that involved partial purification of PARK by chromatography on SP-sepharose followed by stepwise elution with 150 mmol/L NaCl. The ability of partially purified PARK from the various treatment groups to phosphorylate rhodopsin was unaltered, except on PMA treatment in which its activity was reduced -50% compared with control cell preparations (Fig 4B) . Western blot analysis showed significant levels of PARK (-80% recovery from cell lysates) in the 150 m m o l k NaCl fraction, while no GRKS or GRK6 was detected in this fraction (data not shown). Additional evidence that PARK is the major GRK in the IS0 mmolk NaCl fraction is supported by the observations that the rhodopsin phosphorylation was lightdependent and was substantially reduced (>90 %) when preadsorbed with a polyclonal PARK antiserum versus preimmune and nonadsorbed samples (data not shown). Furthermore, G protein P-y subunits, which have been demonstrated LOUDON, PERUSSIA, AND BENOVIC to enhance PARK activity.j5 increased rhodopsin phosphorylation approximately fivefold to sevenfold (data not shown). These data strongly suggest that PARK and GRK6 activities are selectively regulated during HL-60 cell differentiation.
GRK6 and PARK expression in monocytes and peripheral blood lymphocytes stimulated in vitro. Our results demonstrate regulated expression and activity of PARK and GRK6 during differentiation in vitro of the HL-60 promyelomonocytic cell line. To determine if such regulated expression occurs in primary cell cultures, GRK6 and PARK expression was assessed during differentiation of monocytes into mature macrophages in vitro in 3-day cultures with or without 5 pg/ mL LPS."' Irrespective of the presence of LPS, GRK6 protein expression was enhanced in both 3-day cultures over control monocyte levels, while PARK protein levels remained constant (Table l) . These results indicate that PARK and GRK6 expression during monocyte and HL-60 cell differentiation is differentially regulated.
PARK and GRK6 expression was analyzed in lymphoid cells by culturing PBL with several polyclonal activators and assessing kinase mRNA and protein levels. Stimulation of PBL with the T cell polyclonal mitogen PHA4' induced increased expression of both GRK6 transcripts by day I , and a single 67 kD protein was detectable on day 3 at significantly higher levels than in control cells (Fig 5A, top panels, and Table l) . PARK mRNA expression was enhanced by day 1 and peaked on day 3 after PHA stimulation, while PARK protein levels were increased approximately twofold to threefold by day S (Fig SB, top panels, and Table I ).
Increased levels of GRK6 mRNA were detected in PMA and calcium ionophore (A23 187)-treated PBL by day 1 poststimulation, peaked by day 2, and declined slightly by day 3. Expression of a single -67 kD immunoreactive protein rose substantially on day 2 and remained elevated through day 3 (Fig 5A, middle panel, and Table l) . Interestingly, while PARK mRNA levels were increased in these cells over controls on days 2 and 3, PARK protein levels decreased threefold by day 2 (Fig SB, middle panel, and Table l ) . Costimulation of PBL with anti-CD3 and IL-2 induced increased GRK6 mRNA and protein levels by day S. lmmunoblotting showed a -6S/67 kD protein doublet in which the upper band increased -fourfold by day 7 with no apparent change in the 65 kD species (Fig 5A and Table l) . In the same cells, PARK mRNA levels also increased by day 5, while PARK protein expression increased approximately twofold by day 7 (Fig SB, bottom panels) .
The potential for regulated expression of other GRKs in hematopoietic cells was also investigated. Northern blot analysis of GRKS showed no detectable levels of kinase mRNA in untreated or differentiated HL-60 cells or were there any apparent changes in GRKS mRNA accumulation observed in PHA-stimulated PBL or monocytes cultured with LPS (data not shown). GRK4 displays a relatively narrow tissue distribution: mRNA is detected predominantly in and not in PBL, PHA-activated T cell blasts,'"'' (and data not shown), monocytes cultured with and without LPS, or differentiated HL-60 cells (data not shown).
GRK6 and PARK activity in PHA-stimulated PBL. Enhanced PARK and GRK6 activity corresponding to in- creased expression of these kinases was observed in PHAstimulated PBL using the same approaches to assess kinase activity as described for the HL-60 cells (Table 2) . GRK6 activity and expression were increased only approximately twofold versus uninduced PBL for the two donors tested. The increase in GRK6 expression was less compared with other donor PBL stimulated with PHA (see Table 1 ); however, this may reflect variability among the different donor lymphocytes tested. Immunoprecipitation with GRKS/GRK6 antiserum in the presence of competing GST-C terminal GRKS fusion protein significantly reduced phosvitin phosphorylation (>90%) in both control and PHA-stimulated cells (data not shown). PARK-specific activity of SP-sepharose purified fractions was enhanced roughly 2.5-fold and fivefold in PHA-stimulated cells versus control cells for the two donors assayed ( Table 2 ). Similar to our results with partially purified PARK from HL-60 cells, the PARK-enriched fractions exhibited light-dependent activity towards rhodopsin and preadsorption of this kinase with PARK-specific antisera significantly reduced rhodopsin phosphorylation (>90%) versus preimmune serum-adsorbed controls (data not shown). The increased PARK activity in PHA blasts is in agreement with published observations"; furthermore, our data demonstrate that GRK6 activity is also modulated in these cells. However, because PBL also express GRKS," we cannot rule out the possibility that the activity of this kinase is also increased on PHA stimulation because the immunoprecipitating antiserum used in these assays recognizes both GRKS and GRK6. Additionally, these studies do not define whether enhanced GRK expression and activity are directly or indirectly due to T-cell stimulation and proliferation. Nonetheless, these results provide supporting evidence for the regulation of multiple GRK expression and activity patterns in activated lymphocytes.
DISCUSSION
G-protein-coupled receptor kinases regulate the function of a number of seven-transmembrane receptors. The involvement of these kinases in receptor modulation may have functional implications in a variety of cell types and physiological systems, especially given the large number of different G protein-linked receptors and the diverse functions they mediate. Therefore. it is useful to determine the tissue distribution of these kinases and their ability to phosphorylate candidate receptors present in these tissues. The results of this study provide the first evidence for a cell-specific differential regulation of PARK and GRK6 expression and activity: this is observed in myelomonocytic cells during in vitro differentiation in which GRK6 activity and expression are increased. while PARK levels are unchanged. Similarly, PBL stimulated with PMA/calcium ionophore results in increased GRK6 and decreased PARK protein levels, while PHA blasts exhibit increases in the activity and expression of both kinases. These findings suggest that PARK and GRK6 likely play an important role in modulating G-protein-coupled receptor function in immune cells. The increase in PARK expression and activity in PHA-activated PBL is in agreement with a recent report" analyzing GRK mRNA expression and PARK activity in activated T cells. Furthermore, PARK regulation in T lymphocytes appears to be PKC-dependent." In these studies, no change in GRK6 mRNA expression was observed, which differs from our data that demonstrate an increase in GRK6 levels and activity in these cells. One possibility for this could be attributed to differences in the kinetics of increased expression in GRK6 in the two studies. Our observations more clearly establish that PARK activity is enhanced under these conditions because contributing activity from other GRKs (GRKS and GRK6) is eliminated in our purification and assay systems. Furthermore, we show that GRK6 activity is selectively modulated during myelomonocytic cell development using kinase assays of immunoprecipitated GRK6 that allow for functional assessment of this enzyme in the absence of possible contamination from other, more abundant kinases (such as PARK).
Tissue distribution, substrate specificity, and mechanisms -" " and film exposed 72 hours at -80°C. Right panels, Western blots. PARK immunoblots of 30 p g cell lysates with the mouse monoclonal antibody 3A10 were performed as described in (A).
Results are from one experiment representative of two t o four performed.
of PARK activation have been extensively analyzed. Several lines of evidence suggest that PARK is able to phosphorylate a number of G-protein-coupled receptors including the P2AR and the m2AChR.6."'" Transfection of a PARK dominant-negative mutant or treatment of cells with PARK antisense oligodeoxynucleotides resulted in attenuation of agonist-specific desensitization of the /32AR.".5' Isoproterenol and PAF were able to induce PARK cytosol-to-membrane translocation in PBL, suggesting a potential role for PARK in regulation of the P2-adrenergic and PAF receptors."' The substrate specificity of GRK6 is not known, although in vitro studies suggest that GRK6 and PARK specificities are distinct." Whereas PARK phosphorylates the PzAR and the m2AChR to relatively high stoichiometries, GRK6 activity on these substrates is significantly lower. However, it is not known if factors, such as the palmitoylation state of GRKQ'
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or other modifications, significantly affect kinase activity and, thus, account for apparent differences in GRK6 and PARK specificity.
It is not known if regulation of PARK and GRK6 is important during myelomonocytic cell development or at later stages during an immune response when mature neutrophils and monocytes respond to agonists that bind G-proteincoupled receptors (ie, chemotactic agents and inflammatory mediators). The relatively slow kinetics of enhanced GRK6 protein levels in vitro may reflect a preferential requirement for this kinase during later phases of an immune response (eg, possibly at a time when downmodulation of chemoattractant receptor function is required to control an inflammatory response). In situ analysis of GRK expression in lymphoid and myeloid cells that localize to different lymphoid organs (ie, spleen and lymph nodes) and/or site of inflammation during an immune/inflammatory response could shed some light on this issue. Protein kinase C (PKC) plays a key role in T-cell receptor-mediated lymphocyte activation and increased expression of selected PKC isoforms has been described in PBL stimulated with either phorbol ester and calcium ionophore or PHA, which may suggest that regulated expression of a variety of different kinases is necessary on immune cell activation.54355 Regulated expression of additional serinekhreonine kinases in activated T cells has also been d e~c r i b e d .~~ Based on the results with HL-60 cells cultured with OAG, in which PKC is activated in the absence of cell differentiation, we suggest that PKC activation downregulates expression of GRK6 and PARK, albeit to different extents. PMA and lc~,25(0H)~-vitarnin D3 both induce monocytic differentiation of HL-60 cells, but PARK expression is decreased only after PMA treatment and is unaffected in cultures with 1~~,25(0H)~-vitarnin D3. The data with cells cultured with PMA suggest that, although PKC-dependent regulation of PARK expression exists, other factors induced by the phorbo1 ester during cell differentiation may also participate to regulate expression of this kinase. The observations that OAG treatment of HL-60 cells results in a slight decrease in PARK expression and that monocytes and macrophages express similar levels of this kinase suggest that PKC alone is not sufficient to alter PARK expression significantly and that the levels of expression of this kinase do not vary at different stages of monocytic differentiation. Unlike PARK, GRK6 protein expression is increased in HL-60 cells under conditions that induce them to differentiate towards the myeloid and monocyte/macrophage lineages and in peripheral blood macrophages compared with monocytes, possibly indicating an important role for GRK6 during myelomonocytic cell development. The significant reduction in GRK6 levels on treatment of HL-60 cells with OAG and PMA suggests that activation of PKC alone is sufficient for the observed decrease in this kinase.
The low correlation of mRNA and protein expression patterns observed in differentiated monocytes and in PMA/A23-187-treated PBL for PARK (see Fig 5B in which PARK protein decreases after 24 hours, but mRNA levels actually increase) and in DMSO-, RA-, and la,25(OH2)-vitamin D3-treated HL-60 cells for GRK6 may indicate posttranscriptional regulation involving alterations in the half-life of PARK and GRK6 mRNA. Low correlation between mRNA and protein expression patterns has been documented for a variety of genes including secretory protein production during guinea pig seminal vesicle development," the synaptic vesicle proteins, p65 and synaptophysin, during embryogenesis:' immune cell adhesion molecule-l (ICAM-1) expression in glial cells:' and a c-myc regulatory protein, max, in epithelial Clearly, there is a much stronger relationship between expression levels of both proteins and their activity in the kinase assays described (Fig 4) . Also of interest is the apparent differential regulation of expression of the two GRK6 transcripts under certain conditions. Induction of PBL with either PHA or OKT-3 antibody and IL-2 leads to a significant increase in the upper GRK6 transcript with little or no proportional enhancement in expression of the lower mRNA species (Fig 5A) . The significance of this is not clear; however, these results may suggest functional differences exist between the expressed products arising from these transcripts. The presence of the two GRK6 mRNA species does not appear to be due to transcription of two genes, but to either alternative splicing or differential polyadenylation (or both) of transcripts from a single gene on human chromosome 5." Precedence for GRK diversity arising from alternative splicing exists for GRK4 in which four isoforms differing in their predicted NH2-and carboxylterminal sequences have been d e~c r i b e d .~~ Overall, the distinct expression and activation patterns consistently observed for GRK6 and PARK using a variety of compounds that influence hematopoietic cell growth and differentiation in vitro indicate that the two GRKs are regulated on activation or differentiation of these cells. The significance of differentially regulated expression and activity of PARK and GRK6 in myelomonocytic cells may rest in their ability to phosphorylate specific receptors whose expression is also linked to the differentiation status of these cells.
